title: An initial top-down proteomic analysis of the standard cuprizone mouse model of multiple sclerosis.
abstract: An initial proteomic analysis of the cuprizone mouse model to characterise the breadth of toxicity by assessing cortex, skeletal muscle, spleen and peripheral blood mononuclear cells. Cuprizone treated vs. control mice for an initial characterisation. Select tissues from each group were pooled, analysed in triplicate using two-dimensional gel electrophoresis (2DE) and deep imaging and altered protein species identified using liquid chromatography tandem mass spectrometry (LC/MS/MS). Forty-three proteins were found to be uniquely detectable or undetectable in the cuprizone treatment group across the tissues analysed. Protein species identified in the cortex may potentially be linked to axonal damage in this model, and those in the spleen and peripheral blood mononuclear cells to the minimal peripheral immune cell infiltration into the central nervous system during cuprizone mediated demyelination. Primary oligodendrocytosis has been observed in type III lesions in multiple sclerosis. However, the underlying mechanisms are poorly understood. Cuprizone treatment results in oligodendrocyte apoptosis and secondary demyelination. This initial analysis identified proteins likely related to axonal damage; these may link primary oligodendrocytosis and secondary axonal damage. Furthermore, this appears to be the first study of the cuprizone model to also identify alterations in the proteomes of skeletal muscle, spleen and peripheral blood mononuclear cells. Notably, protein disulphide isomerase was not detected in the cuprizone cohort; its absence has been linked to reduced major histocompatibility class I assembly and reduced antigen presentation. Overall, the results suggest that, like experimental autoimmune encephalomyelitis, results from the standard cuprizone model should be carefully considered relative to clinical multiple sclerosis.
authors: Department of Molecular Physiology, School of Medicine, University of Western Sydney, Penrith, NSW Australia ; Molecular Medicine Research Group, School of Medicine, University of Western Sydney, Penrith, NSW Australia.
authors: Melissa A
authors: MA
authors: Partridge
authors: Molecular Medicine Research Group, School of Medicine, University of Western Sydney, Penrith, NSW Australia ; Department of Neurology, Campbelltown Hospital, Campbelltown, NSW Australia.
authors: Sumana
authors: S
authors: Gopinath
authors: Molecular Medicine Research Group, School of Medicine, University of Western Sydney, Penrith, NSW Australia ; Neuro-Cell Biology Laboratory, School of Science and Health, University of Western Sydney, Penrith, NSW Australia.
authors: Simon J
authors: SJ
authors: Myers
authors: Department of Molecular Physiology, School of Medicine, University of Western Sydney, Penrith, NSW Australia ; Molecular Medicine Research Group, School of Medicine, University of Western Sydney, Penrith, NSW Australia.
authors: Jens R
authors: JR
authors: Coorssen
keywords: Autoimmunity; Multiple sclerosis; Neurodegeneration; Oligodendrocytosis